NCT05633654 · Interventional trial
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Overall registry status Recruiting
Phase 3
Conditions Triple Negative Breast Cancer
Delaware Valley sites
- University of Pennsylvania Abramson Cancer Center · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory